ISSN 2410-7751 (Print)
ISSN 2410-776X (Online)
Biotechnologia Acta V. 15, No. 5, 2022
P. 64-70. Bibliogr. 13 , English.
UDC: 616.72-002-074:
https://doi.org/10.15407/biotech15.05.064
PHYTOCHEMICAL CONSTITUENTS AND ANTILEUKEMIC EFFECTS OF JUNIPERUS OXYCEDRUS EXTRACT
1 Department of Bioengineering, Faculty of Engineering and Natural ciences, Üsküdar University, Istanbul, Turkey.
2Department of Pharmaceutical Botany, Faculty of Pharmacy, İstanbul University, İstanbul, Turkey.Department of Bioengineering, Faculty of Engineering and Natural
Aim: Many genetic and environmental factors can be effective in the process of cancerization. Preventing the progression of leukemia may be possible by controlling the pathways involving mechanisms such as apoptosis and autophagy. When the literature is examined, there are studies showing the effects of various types of juniper on various cancer cell lines, including human chronic myeloid leukemia cells, but the signal pathways in which they act are not fully known. In this study, the anticancer effects of Juniperus oxycedrus extract on K-562 human chronic myeloid leukemia cells were investigated.
Method: After the cells were treated with the Juniperus oxycedrus extract, cytotoxicity and gene expression analyzes were performed. Changes in the expression of Akt, the member of the PI3K/Akt/mTOR signaling pathway; caspase 3, which is one of the main effective genes in the pathways regulating apoptosis; and the apoptosis suppressor BCL-2 gene, which is an oncogene, were investigated.
Results: According to the MTT test results, Juniperus oxycedrus extract showed over approximately 50% cell viability in K-562 cells at all doses. The most appropriate dose of Juniperus oxycedrus fruit extract in this research was determined as 50 µg/ mL considering cell viability. After the gene expression analysis, it was observed that Akt expression increased 1.092 times, BCL-2 expression decreased approximately 0.3 times, and caspase 3 expression increased 1.2 times.
Conclusions: Constituents of Juniperus oxycedrus plant may have apoptotic effects on chronic myeloid leukemia cells.
Key words: Juniperus oxycedrus, leukemia, apoptosis.
© Palladin Institute of Biochemistry of National Academy of Sciences of Ukraine, 2022
References
1. Calabretta B., Salomoni P. Inhibition of autophagy: A new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors. Leukemia and Lymphoma. 2011, p 54‒59. https://doi.org/10.3109/10428194.2010.546913
2. Ciaffaglione V., Consoli V., Intagliata S., Marrazzo A., Romeo G., Pittalà V., Greish K., Vanella L., Floresta G., Rescifina A., Salerno L., Sorrenti V. Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia. Molecules 2022, 27(10):3220. https://doi.org/10.3390/molecules27103220
3. Öztürk M., Tümen I., Uǧur A., Aydoǧmuş-Öztürk F., Topçu G. Evaluation of fruit extracts of six Turkish Juniperus species for their antioxidant, anticholinesterase and antimicrobial activities. Journal of the Science of Food and Agriculture. 2011, 91(5):867‒876. https://doi.org/10.1002/jsfa.4258
4. Akkol EK., Güvenç A., Yesilada E. A comparative study on the antinociceptive and anti-inflammatory activities of five Juniperus taxa. Journal of Ethnopharmacology. 2009, 125(2):330‒336. https://doi.org/10.1016/j.jep.2009.05.031
5. Karaman I., Şahin F., Güllüce M., Öǧütçü H., Şengül M., Adigüzel A. Antimicrobial activity of aqueous and methanol extracts of Juniperus oxycedrus. L. Journal of Ethnopharmacology. 2003, 85(2‒3), 231‒235. https://doi.org/10.1016/S0378-8741(03)00006-0
6. Huyan T., Li Q., Wang YL., Li J., Zhang JY., Liu YX., Shahid MR., Yang H., Li HQ. Anti-tumor effect of hot aqueous extracts from Sonchus oleraceus (L.) L. and Juniperus sabina L - Two traditional medicinal plants in China. Journal of Ethnopharmacology. 2016, 185, 289‒299. https://doi.org/10.1016/j.jep.2016.03.044
7. Khuda F., Alam N., Khalil AAK., Jan A., Naureen F., Ullah Z., Alotaibi A., Ullah R., Ullah S., Shah Y., Shah SI., Büyüker SM. Screening of Rhamnus Purpurea (Edgew.) Leaves for Antimicrobial, Antioxidant, and Cytotoxic Potential. ACS Omega. 2022, 7(26), 22977–22985. https://doi.org/10.1021/acsomega.2c03094
8. Atasever-Arslan B., Yilancioglu K., Kalkan Z., Timucin AC., Gür H., Isik FB., Deniz E., Erman B., Cetiner S. Screening of new antileukemic agents from essential oils of algae extracts and computational modeling of their interactions with intracellular signaling nodes. European Journal of Pharmaceutical Sciences. 2016, 83:120-31. https://doi.org/10.1016/j.ejps.2015.12.001
9. Atasever B., Akgün DK., Kuruca S., Turan N., Seyhanli V MA. Effects of flavonoids obtained from Cynara syriaca on leukemic cells. Ankara University Faculty of Pharmacy Journal. 2003, 32(3), 143‒150. https://doi.org/10.1501/Eczfak_0000000406
10. De Kouchkovsky I., Abdul-Hay M. 'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J. 2016, 6(7),441. https://doi.org/10.1038/bcj.2016.50
11. Wu P.S., Wang C.Y., Chen P.S., Hung J.H., Yen J.H., Wu M.J. 8-Hydroxydaidzein Downregulates JAK/STAT, MMP, Oxidative Phosphorylation, and PI3K/AKT Pathways in K562 Cells. Biomedicines. 2021, 9(12), 1907. https://doi.org/10.3390/biomedicines9121907
12. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., Cervantes F., Deininger M., Gratwohl A., Guilhot F., Hochhaus A., Horowitz M., Hughes T., Kantarjian H., Larson R., Radich J., Simonsson B., Silver RT., Goldman J., Hehlmann R. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology. 2009, p 6041‒6051. https://doi.org/10.1200/JCO.2009.25.0779
13. Ivanova D.I., Nedialkov P.T., Tashev A.N., Olech M., Nowak R., Ilieva Y.E., Kokanova-Nedialkova Z.K., Atanasova T.N., Angelov G., Najdenski H.M. Junipers of various origins as potential sources of the anticancer drug precursor podophyllotoxin. Molecules. 2021, 26(17), 5179. https://doi.org/10.3390/molecules26175179
14. Sanna B., Debidda M., Pintus G., Tadolini B., Posadino AM., Bennardini F., Sava G., Ventura C. The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway. Archives of Biochemistry and Biophysics. 2002, 403(2), 209‒218. https://doi.org/10.1016/s0003-9861(02)00218-7
15. Hers I., Vincent E.E., Tavaré J.M. Akt signalling in health and disease. Cellular Signalling. 2011, p 1515‒1527. https://doi.org/10.1016/j.cellsig.2011.05.004
16. Altomare D.A., Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005, p 7455‒7464. https://doi.org/10.1038/sj.onc.1209085
17. Khan N., Kahl B.Targeting BCL-2 in Hematologic Malignancies. Targeted Oncology. 2018, p 257‒267. https://doi.org/10.1007/s11523-018-0560-7